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Eukaryotic initiation factor 2Increasing recognition of the interaction between the brain and gut microbiota has spurred interest in the
efficacy of probiotics on stress-related behaviours. This study aimed to elucidate the effects of
Lactobacillus gasseri CP2305 (CP2305) on mental and physical states in healthy male students enrolled
in a cadaver dissection course in a double-blinded, placebo-controlled, crossover-designed trial. Daily
administration of CP2305 for 4 weeks significantly improved anxiety, depressive mood and global sleep
quality compared with placebo. CP2305 also suppressed salivary cortisol release. In the faecal microbiota,
CP2305 suppressed the growth of Enterobacteriaceae. Differential changes in gene expression in periph-
eral blood leukocytes during the administration period were observed between the placebo and CP2305
groups. Eukaryotic initiation factor 2-related genes were down-regulated only in the placebo group. Thus,
the ingestion of CP2305 may have beneficial effects on stress-associated behaviours.
 2017 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Several lines of evidence have suggested that the gut microbiota
can profoundly modulate communication between the gut and the
brain (De Palma, Collins, Bercik, & Verdu, 2014) via neural, endo-
crine, and immune signalling pathways (Cryan & Dinan, 2012;
Montiel-Castro, González-Cervantes, Bravo-Ruiseco, & Pacheco-
Lopez, 2013). This concept is now interpreted broadly as the micro
biota–gut–brain axis (Bercik, 2011). The gut microbiota affect host
stress sensitivity via brain-gut interactions. The relationship
between stress and gut microbiota has begun to garner attention
(De Palma et al., 2014). With respect to stress management, it is
important to uncover whether and how probiotics can influence
stress-related behaviours. Animal studies have demonstrated that
the administration of probiotics mitigates stress-induced glucocor-
ticoid and inflammatory cytokine responses in association with
reductions in depression- and anxiety-related behaviours (Ait-
Belgnaoui et al., 2012, 2014; Bercik et al., 2011; Bravo et al.,
2011; Gareau, Jury, MacQueen, Sherman, & Perdue, 2007;
Messaoudi et al., 2011). Clinical trials have demonstrated that pro-biotics exert beneficial effects by alleviating psychological distress
in healthy subjects (Messaoudi et al., 2011) and normalizing stress-
induced reductions in natural killer (NK) cell numbers (Marcos
et al., 2004) and gastrointestinal symptoms (Diop, Guillou, &
Durand, 2008).
We employed medical students enrolled in a cadaver dissection
course to test the stress-relieving effect of a probiotic, Lactobacillus
gasseri CP2305 (CP2305). Gross anatomy is one of the most impor-
tant subjects in the preclinical part of medical education. A number
of studies around the world have investigated student responses to
the dissection of a human corpse and how to mitigate mental dis-
tress in the dissection room (Bob, Popescu, Armean, Suciu, &
Buzoianu, 2014; Russa & Mligiliche, 2014). Bernhardt, Rothkötter,
and Kasten (2012) reported that approximately 50% of German
medical students began a dissection course with emotional stress,
and approximately one-tenth of them were very concerned about
being confronted with corpses. Although the attitudes of students
in Japanese medical schools towards the dissecting room have
been found to be consistently positive during the course, the cada-
ver dissection course is unquestionably the most stressful curricu-
lum for pre-clinical students.
We originally isolated a unique strain, CP2305, from stool sam-
ples of a healthy volunteer in 1994. CP2305 has an antiflatulent
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changes to the composition of their microbiota. It can colonize
the digestive tracts of volunteers at a rate of approximately 40%
after oral administration 3 times at the dose of 1.0  1011 CFU
(Sawada et al., 2016; Sugawara et al., 2016). Recently, we showed
that a 4-week administration of CP2305 significantly improved the
clinical symptoms of patients with irritable bowel syndrome (IBS)
and significantly improved their QOL through the reduction of
‘‘health-related worry” (Nobutani et al., 2017). IBS symptoms are
closely associated with psychosocial stress. Based on these find-
ings, we conducted a double-blinded, placebo-controlled,
parallel- and crossover-group trial to examine whether CP2305
alleviated stress-associated behaviours in medical students
enrolled in a cadaver dissection course.2. Materials and methods
2.1. Probiotics
CP2305 was originally isolated in 1994 from stool samples of a
healthy volunteer at the R&D Center of Asahi Group Holdings, Ltd.
(Kanagawa, Japan). Whole 16S ribosome DNA (16S-rDNA)
sequence analysis and DNA-DNA hybridization of its genomic
DNA with that of the type strain L. gasseri (ATCC 33323T) identified
this strain as L. gasseri. The safety of L. gasseri has been authorized
by the European Food Safety Authority, and it is listed under the
Qualified Presumption of Safety. CP2305 was cultured at 37 C
for 24 h in medium containing 10% skim milk and 0.25% yeast
extract. The cultured medium was lyophilized and disintegrated
by a food processor mill (TESCOM, Tokyo, Japan). The powder
(2.5 g) containing CP2305 (1.0  1010 CFU) was packed in a dispos-
able aluminium bag for single ingestion. The same amount of lyo-
philized powder prepared from the dispersion liquid containing
skimmilk (20%) and yeast extract (0.50%) was packed into a similar
bag to serve as the placebo supplement. Subjects consumed the
powder after dissolving it in water. The appearance and taste of
both the test and placebo drinks could not be distinguished by sen-
sory assessment. The CP2305 and placebo formulations were pre-
pared in accordance with Japan’s Food Sanitation Law and passed
safety inspection.2.2. Subjects and protocol
A double-blinded, placebo-controlled, crossover trial was con-
ducted. We recruited 24 s-year medical students at Tokushima
University, Tokushima, Japan. All participants were male students.
Participants were not habitual smokers and had not taken medica-
tion for 3 months prior to enrolment. None of the students had
mental or other diseases or allergies to milk or other foods. The
students were taking the cadaver dissection course from Septem-
ber 1st to December 9th. As part of the crossover trial design, theGroup 1
Group 2 CP2305 PlaceboWashout
Sampling Sampling Sampling Sampling
Placebo CP2305Washout
First admin.
for 4 weeks
Second admin.
for 4 weeks
Interval
for 3 weeks
Fig. 1. Examination schedule. Participants were divided into 2 groups. Participants
in group 1 were first administered the placebo, entered a wash-out period, and
subsequently received CP2305. Those in group 2 were administered CP2305 and the
placebo in the opposite order. Biological samples and questionnaire responses were
obtained at the start and end of each experimental period.students were randomly divided into 2 groups. As shown in
Fig. 1, participants allocated to group 1 consumed the placebo once
a day throughout the first experimental period of 4 weeks. After a
3-week wash out period, they consumed the CP2305 supplement
once a day for 4 weeks during the second administration period.
Participants allocated to group 2 followed the opposite protocol.
Daily consumption was self-recorded in a diary to determine the
compliance rate of ingestion. During the trial, the subjects com-
plied with dietary restrictions to avoid the consumption of other
fermented milks, fermented foods, beverages containing living lac-
tic acid bacteria, and probiotic or prebiotic products. Medications
and hospital visits were allowed and recorded in a diary if these
events occurred. This study was conducted according to the guide-
lines given in the Declaration of Helsinki, and all procedures
involving human subjects were approved by the Institutional
Review Board of Tokushima University Hospital, Tokushima, Japan.
Written informed consent was obtained from all participants prior
to enrolment.
2.3. Self-reported measurements of mental and physical states
The physical and mental health of the participants was assessed
using the following questionnaires: GHQ28, the 28-item General
Health Questionnaire (Goldberg & Hillier, 1979); Zung-SDS, the
Zung Self-rating Depression Scale (Zung, 1965); HADS, the Hospital
Anxiety and Depression Scale (Zigmond & Snaith, 1983); and STAI,
the Spielberger State-Trait Anxiety Inventory (Kvaal, Ulstein,
Nordhus, & Engedal, 2005). Sleep was evaluated using the Pitts-
burgh Sleep Quality Index (PSQI) (Buysse, Reynolds, Monk,
Berman, & Kupfer, 1989), which assesses sleep quality and distur-
bances over a 1-month time interval. The PSQI is a 19-item ques-
tionnaire; individual items were combined to form the following
seven components: sleep disturbance, overall sleep quality, sleep
latency, duration of sleep, daytime dysfunction due to sleepiness,
sleep efficiency, and need for sleep medication A total score, rang-
ing from 0 to 21, was obtained by adding these seven component
scores. Scores >5 suggest poor sleep quality, whereas scores 65
suggest good sleep quality (Buysse et al., 1989, 2008). These ques-
tionnaires were given to the subjects at the time of blood sampling.
Gastrointestinal symptoms of the participants were assessed
using a 100-mm visual analogue scale (VAS) concerning abdomi-
nalgia, feelings of indigestibility, anorexia, borborygmus, abdomen
distension, abdominal discomfort, diarrhoea, constipation, fre-
quency of defecation, and colour of faeces. Eating behaviour was
assessed using the Eating Attitudes Test with 26 items (EAT-26),
which is a self-report measure of eating disorder symptoms that
is widely used for the screening and measurement of symptoms
and characteristics of eating disorders (Garner, Olmsted, Bohr, &
Garfinkel, 1982).
2.4. Measurements of salivary cortisol, alpha-amylase and
chromogranin A
Saliva was collected for 2 min between 16:00 and 17:00 to
avoid diurnal fluctuations using a Salivette sampling device (Sar-
stadt Inc., Rommelsdorf, Germany) prior to the collection of blood
(Kurokawa et al., 2010), and samples were stored at 80 C until
analysis. Salivary chromogranin A (CgA), cortisol, and alpha-
amylase were assayed using kits (YK070 Human CgA EIA Kit,
Yanaihara Institute, Shizuoka, Japan; Salivary Cortisol EIA Kit and
Alpha-Amylase Assay Kit, Salimetrics Inc., LLC, Carlsbad, CA, USA).
2.5. Analysis of faecal microbiota
Faecal samples were collected once during the 3 days prior to
the previously appointed date before and after the administration
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tivation method developed by Mitsuoka (Mitsuoka, Ohno, Benno,
Suzuki, & Nanba, 1976; Mitsuoka, Sega, & Yamamoto, 1965).2.6. Gene expression profiling of peripheral blood cells
Venous blood (2.5 ml) was collected from each subject between
16:00 and 17:00 and immediately poured into PAXgene blood RNA
tubes (Becton Dickinson, Franklin Lakes, NJ, USA). After sufficient
mixing, the tubes remained at room temperature for 2 h and were
then stored at 80 C until analysis. RNA was isolated using a PAX-
gene Blood RNA Kit (Qiagen, Hilden, Germany) according to the
manufacturer’s protocol. Contaminated DNA was removed using
a DNase kit (Qiagen). Purified RNA quality was assessed with an
Agilent 2100 Bioanalyzer using an RNA 6000 Nano Labchip Kit
(Agilent Technologies, Santa Clara, CA, USA), and RNA samples with
>8.5 RNA integrity number (RIN) were used for further
measurements.
The RNA samples were subjected to gene expression analysis
using a whole human genome microarray (4  44 k ver. 2.0, Agi-
lent Technologies) as previously described (Kuwano et al., 2011).
Microarray data were analysed with GeneSpring 11.5.1 (Agilent
Technologies). The functional pathways related to the set of differ-
entially expressed genes were assessed using Ingenuity Pathway
Analysis (IPA) 9.0 (http://www.ingenuity.com) (Kuwano et al.,
2011). The probability of a relationship between each biologicalPlacebo   CP2305 
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combined because the probability of the factor ‘‘Period” was not significant, panels (B)function and the identified genes was calculated by Fisher’s exact
test. The level of significance was set at a p value of 0.05.2.7. Statistical analyses
All statistical analyses were performed using SAS ver. 9.2 and
JMP11 Pro (SAS Institute Japan Ltd., Tokyo, Japan). We analysed
the results of all the questionnaires and assessed differences in
salivary hormones and faecal microbiota before and after interven-
tion using a mixed-model analysis of variance (ANOVA) for cross-
over design. We paid close attention to the statistical significance
of the factor ‘‘Treatment”. Values less than 0.05 indicated a signif-
icant difference in both treatments. If the statistical significance of
the factor ‘‘Period” was equal to or greater than 0.05, Welch’s t-test
was applied to compare the final and initial data for the ingestion
periods with each treatment over both experimental periods.3. Results
3.1. Effects of CP2305 ingestion on mental state
We first assessed whether CP2305 administration influenced
the mental state of the participants. Using box-whisker plots, we
plotted the time-dependent changes in STAI-state scores for
groups 1 and 2 (Fig. 2A). There were marked individual variations
in the scores during the course. Students taking placebo tended to  CP2305 
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moderate to severe anxiety. In contrast, CP2305 ingestion
appeared to reduce STAI-state scores in both group 1 (1st adminis-
tration) and group 2 (2nd administration). The CP2305- andTable 1
ANOVA results for changes in the scores of mental health questionnaires before and after
Questionnaire Probability for each factora
Group Individual Period Treatment
GHQ28
Total score 0.290 0.104 0.912 0.978
Physical symptom 0.087 0.556 1.000 0.311
Depression 0.020 0.038 0.589 0.589
Anxiety and insomnia 0.409 0.013 0.839 0.207
HADS
Depression 0.798 0.437 0.626 0.020*
Anxiety 0.781 0.350 0.917 0.040*
STAI
State anxiety 0.157 0.041 0.335 0.040*
Trait anxiety 0.993 0.019 0.566 0.147
Zung-SDS
Depression 0.003 0.448 0.734 0.975
EAT26
Eating behaviour 0.929 0.455 0.097 0.278
PSQI
Global PSQI 0.034 0.761 0.059 0.046*
Disturbance 0.233 0.604 0.345 0.041*
a ANOVA with a mixed model for crossover design was applied.
b Welch’s t-test was applied to compare the final and initial data for each ingestion per
factor ‘‘Period” was not significant.
* The probability was less than 0.05.
Table 2
ANOVA results for changes in the scales of abdominal symptom questionnaires before and
Questionnaire Probability for each factora
Group Individual Period Treatment
Abdominal pain 0.031 0.520 0.615 0.050
Heavy stomach 0.096 0.569 0.728 0.055
Anorexia 0.041 0.749 0.671 0.071
Borborygmus 0.351 0.983 0.987 0.129
Colour tone 0.050 0.061 0.289 0.204
Defecation frequency 0.724 0.625 0.301 0.365
Abdominal fullness 0.513 0.834 0.806 0.396
Diarrhoea 0.945 0.973 0.628 0.633
Abdominal discomfort 0.823 0.735 0.451 0.819
Constipation 0.019 0.545 0.783 0.451
a ANOVA with a mixed model for crossover design was applied.
b Welch’s t-test was applied to compare the final and initial data for each ingestion per
factor ‘‘Period” was not significant.placebo-treated groups during the first and second administration
periods were mixed together because the probabilities of all items
falling under the term of ‘‘Period” were not significant. The initial
scores for all of the questionnaires, including STAI scores, and allthe intervention periods in the crossover design.
Treatment Initial scores Changes in scores
Mean SEM Mean SEM Probabilityb
Placebo 18.65 2.10 1.08 1.45 0.465
CP2305 20.22 2.61 1.14 1.58 0.480
Placebo 4.91 0.62 0.08 0.59 0.891
CP2305 4.96 0.79 0.82 0.62 0.205
Placebo 0.87 0.30 0.40 0.31 0.212
CP2305 1.26 0.38 0.15 0.34 0.667
Placebo 3.70 0.54 1.08 1.45 0.465
CP2305 4.13 0.65 1.14 1.58 0.480
Placebo 4.48 0.81 1.36 0.69 0.063
CP2305 6.96 1.04 1.24 0.75 0.116
Placebo 4.20 0.92 2.28 0.65 0.150
CP2305 5.75 1.16 0.18 0.68 0.631
Placebo 36.70 1.85 3.99 1.56 0.075
CP2305 40.26 3.28 1.39 1.80 0.231
Placebo 38.20 2.69 2.88 0.77 0.462
CP2305 41.79 3.57 1.08 0.89 0.517
Placebo 36.87 1.75 0.27 1.10 0.808
CP2305 37.57 1.83 0.32 1.15 0.783
Placebo 42.96 2.43 0.94 1.07 0.392
CP2305 40.48 2.30 2.71 1.16 0.031*
Placebo 4.09 0.72 1.79 0.56 0.005*
CP2305 4.00 0.44 0.09 0.56 0.880
Placebo 0.64 0.22 0.29 0.11 0.069
CP2305 1.44 0.28 0.14 0.11 0.782
iod and each treatment over both experimental periods where the probability of the
after the intervention periods in the crossover design.
Treatment Initial values
(cm)
Changes (cm)
Mean SEM Mean SEM Probabilityb
Placebo 13.76 5.17 5.30 3.39 0.146
CP2305 13.64 5.63 5.36 3.54 0.156
Placebo 12.76 5.25 5.68 3.61 0.144
CP2305 12.72 5.66 5.62 3.71 0.158
Placebo 5.33 2.31 8.74 4.23 0.065
CP2305 7.85 3.48 4.38 4.74 0.377
Placebo 12.78 4.53 4.84 6.33 0.460
CP2305 23.38 5.80 10.08 6.62 0.153
Placebo 8.79 3.22 1.98 2.20 0.385
CP2305 13.12 3.98 2.29 2.30 0.339
Placebo 14.18 4.09 6.10 6.50 0.366
CP2305 15.09 5.01 2.75 6.79 0.693
Placebo 15.56 5.43 4.55 5.35 0.412
CP2305 19.78 5.48 2.25 5.58 0.694
Placebo 21.14 5.89 0.45 7.28 0.952
CP2305 23.53 7.00 5.61 7.60 0.475
Placebo 18.43 4.53 3.20 4.13 0.453
CP2305 17.90 5.40 1.81 4.31 0.682
Placebo 16.02 5.56 0.41 4.81 0.933
CP2305 11.17 3.92 5.90 5.23 0.280
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Table 3
ANOVA results for the changes in stress biomarker measurements before and after each intervention period in the crossover design.
Item measured Probability for each factora Treatment Initial values Changes
Group Individual Period Treatment Mean SEM Mean SEM Probabilityb
Cortisol 0.529 0.350 0.620 0.023* Placebo 0.64 0.10 0.12 0.09 0.203
CP2305 0.68 0.07 0.20 0.09 0.041*
Chromogranin A 0.014 0.043 0.613 0.081 Placebo 3.96 1.17 1.28 1.05 0.257
CP2305 3.50 0.95 1.51 1.05 0.167
Amylase 0.050 0.521 0.288 0.159 Placebo 158.40 26.55 114.86 60.82 0.073
CP2305 185.30 54.05 8.13 58.23 0.890
a ANOVA with a mixed model for crossover design was applied.
b Welch’s t-test was applied to compare the final and initial data for each ingestion period and each treatment over both experimental periods when the probability of the
factor ‘‘Period” was not significant.
* The probability was less than 0.05.
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are summarized in Table 1. CP2305 tended to improve anxiety dur-
ing the course, which was assessed using the two questionnaires
STAI-state (p = 0.040; Fig. 2B) and HADS-anxiety (p = 0.040;
Fig. 2C). Although CP2305 administration did not affect depressive
mood as assessed by SDS, it significantly improved depressive
mood, estimated by the HADS-depression score (p = 0.020;
Fig. 2D).3.2. Effects of CP2305 ingestion on stress-induced sleep disturbance
The box-whisker plots of global PSQI scores shown in Fig. 3A
indicate that after starting the course, students taking placebo
developed sleep disturbances that gradually progressed during
the cadaver dissection course. CP2305 ingestion appeared to pre-
vent the development of sleep disturbance (Fig. 3A). The daily
intake of CP2305 significantly prevented increases in PSQI global
Table 4
ANOVA results for changes in the microbiota composition before and after each intervention period in the crossover design.
Bacterial group Probability for each factora Treatment Initial values
(log cfu/g)
Changes (log cfu/g)
Group Individual Period Treatment Mean SEM Mean SEM Probabilityb
Enterobacteriaceae 0.157 0.744 0.925 0.018* Placebo 6.73 0.26 0.87 0.30 0.007*
CP2305 7.40 0.19 0.22 0.30 0.465
Lactobacillus 0.363 0.708 0.260 0.073 Placebo 4.57 0.45 0.42 0.30 0.297
CP2305 4.58 0.34 0.65 0.41 0.127
Veillonella 0.0001 0.851 0.842 0.094 Placebo 2.71 0.15 1.16 0.49 0.029*
CP2305 3.31 0.19 0.07 0.49 0.891
Eubacterium 0.240 0.548 0.888 0.257 Placebo 9.56 0.13 0.16 0.18 0.407
CP2305 9.41 0.13 0.13 0.17 0.430
Megasphaera 0.155 0.501 0.329 0.329 Placebo 2.32 0.32 0.02 0.01 0.994
CP2305 2.33 0.33 0.00 0.01 0.368
B. fragilis group 0.898 0.995 0.185 0.364 Placebo 9.05 0.28 0.47 0.35 0.197
CP2305 9.01 0.18 0.01 0.35 0.985
Staphylococcus 0.687 0.385 0.685 0.445 Placebo 2.71 0.15 0.07 0.24 0.769
CP2305 3.33 0.19 0.20 0.24 0.430
M. hypermegas 0.261 0.501 0.431 0.519 Placebo 2.56 0.39 0.004 0.52 0.994
CP2305 3.00 0.47 0.48 0.52 0.368
Bacteroidaceae 0.228 0.0001 0.062 0.548 Placebo 9.93 0.14 0.19 0.08 0.024*
CP2305 9.79 0.14 0.27 0.08 0.005*
Clostridium 0.0003 0.535 0.521 0.666 Placebo 8.01 0.44 0.03 0.28 0.914
(Lecithinase-) CP2305 8.73 0.20 0.13 0.24 0.595
Enterococcus 0.024 0.028 0.308 0.788 Placebo 6.49 0.31 0.04 0.27 0.871
CP2305 6.63 0.32 0.15 0.27 0.588
Bacillus 0.981 0.808 0.099 0.651 Placebo 2.44 0.22 0.43 0.52 0.416
CP2305 2.75 0.37 0.09 0.52 0.858
Yeast 0.860 0.398 0.335 0.713 Placebo 2.59 0.17 0.41 0.18 0.040*
CP2305 2.65 0.18 0.31 0.20 0.148
Bifidobacterium 0.641 0.637 0.210 0.751 Placebo 9.70 0.13 0.03 0.18 0.856
CP2305 9.43 0.11 0.05 0.18 0.789
Clostridium 0.300 0.005 0.742 0.870 Placebo 2.95 0.35 0.13 0.45 0.780
(Lecithinase + ) CP2305 3.45 0.36 0.02 0.45 0.963
P. aeruginosa 0.491 0.601 0.212 0.912 Placebo 2.08 0.07 0.05 0.05 0.272
CP2305 2.06 0.04 0.06 0.05 0.213
a ANOVA with a mixed model for crossover design was applied.
b Welch’s t-test was applied to compare the final and initial data for each ingestion period and each treatment over both experimental periods where the probability of the
factor ‘‘Period” was not significant.
* The probability was less than 0.05.
194 D. Sawada et al. / Journal of Functional Foods 31 (2017) 188–197scores (p = 0.046; Fig. 3B). The global PSQI score is the sum of seven
component scores (sleep disturbance, overall sleep quality, sleep
latency, duration of sleep, daytime dysfunction due to sleepiness,
sleep efficiency, and need for medicines to sleep). Among them,
CP2305 significantly improved the PSQI-disturbance score
(p = 0.041; Fig. 3C).3.3. Effects of CP2305 ingestion on abdominal symptoms and salivary
stress markers
All initial scores for abdominal symptoms and their changes
before and after intervention are summarized in Table 2. Compared
with the placebo group, the CP2305-treated group exhibited
improvements in abdominalgia (p = 0.050), feelings of indigestibil-
ity (p = 0.055) and anorexia (p = 0.071; Fig. 4).
In addition to the above self-reported measurements, we
assessed the effects of CP2305 by measuring salivary stress mark-
ers (cortisol, CgA, and a-amylase). All initial values and their
changes before and after intervention are listed in Table 3. As
shown in Fig. 5A, CP2305 intake appeared to reduce salivary corti-
sol levels in group 1 and group 2 during the second and first
administration periods, respectively. In fact, CP2305 administra-
tion significantly reduced salivary cortisol levels compared with
the levels before the intervention period (p = 0.041), and the
changes in those values between the CP2305 and placebo groups
were significantly different (p = 0.023; Fig. 5B). At the same time,
CP2305 tended to suppress the increase in CgA levels observed in
the placebo group (p = 0.081; Fig. 5C). Ingestion tended to increasesalivary a-amylase release in the placebo group (p = 0.073),
whereas this trend was not present in the CP2305-treated group,
although the difference between the treatments was not signifi-
cant (p = 0.159; Table 3).
3.4. Effects of CP2305 ingestion on faecal microbiota
Sixteen groups of microorganisms were identified by their
growth on selective medium, colony shape, and Gram staining as
follows: Bacillus, Bacteroides fragilis group, Bacteroidaceae, Bifi-
dobacterium, Clostridium (Lecithinase+), Clostridium (Lecithinase-),
Enterobacteriaceae, Enterococcus, Eubacterium, Lactobacillus, Mega-
monas hypermegas, Megasphaera, Pseudomonas aeruginosa, Staphy-
lococcus, Veillonella, and yeasts. All of the changes are
summarized in Table 4. Among these taxa, Enterobacteriaceae
and Veillonella were significantly increased after intervention only
in samples from the placebo subjects (p = 0.007, p = 0.029, respec-
tively; Table 4). However, the increase in Enterobacteriaceae was
significantly inhibited in the CP2305 group compared with the pla-
cebo group (p = 0.018; Fig. 6A). Tendencies towards increased Lac-
tobacillus and suppressed increases in Veillonella were also
observed (p = 0.073, p = 0.094, respectively; Fig. 6B and C).
3.5. Changes in gene expression in peripheral blood leukocytes
Finally, we tested whether stress-related gene expression signa-
tures could be detected in peripheral blood leukocytes in the pla-
cebo group, and we examined how CP2305 administration
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Fig. 6. Changes in the composition of the faecal microbiota. Changes in the populations of faecal Enterobacteriaceae (A), Lactobacillus (B) and Veillonella (C) are presented.
Data are expressed as the mean ± SEM of the change in each population before and after treatment. Open and filled bars represent the placebo and CP2305 periods,
respectively. Statistical analysis was performed by mixed-model ANOVA for crossover design, and p values indicate significant probabilities of the term of ‘‘Treatment”. Data
from both groups in the same treatment were integrated for evaluation because the probability of the factor ‘‘Period” was not significant.
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prior to administration significantly affected the assessment of
gene expression changes in a limited number of subjects. We
therefore compared the gene expression profile of each student
before and after the administration of CP2305 or placebo.
The students in the placebo and CP2305 groups exhibited sig-
nificant changes in the expression levels of 829 and 1083 genes,
respectively. Among them, the expression of 327 genes changed
in the same directions in both the placebo- and CP2305-treated
groups. The 829 and 1083 affected genes were subjected to path-
way analysis using IPA. As shown in Fig. 7A (left panel), IPA listed
the top 5 canonical pathways related to the 829 affected genes in
the placebo group as follows: (1) EIF2 Signalling (p = 2.86E14),
(2) mTOR Signalling (1.38E06), 3) Regulation of eIF4 and
p70S6K Signalling (1.57E06), 4) TCA Cycle II (1.37E04), and 5)
Mitochondrial Dysfunction (1.79E04). The 4-week administration
of CP2305 significantly changed the expression of 1083 genes in
total, and the top 5 canonical pathways related to the 1083 genes
were the following: (1) TCA Cycle II (6.20E04), (2) ERK5 Signalling
(8.17E4), (3) Hypoxia Signalling in the Cardiovascular System
(1.05E3), (4) Superpathway of Inositol Phosphate Compounds
(5.48E3), and (5) Lipid Antigen Presentation by CD1 (7.32E03)
(Fig. 7A, right panel). Considering the p values of the listed canon-
ical pathways, the most prominent changes in gene expression
were related to the EIF2 pathway in the placebo group. As shown
in Fig. 7B (left panel), most of the EIF2-related genes were down-
regulated in the placebo group. Notably, CP2305 administration
prevented the down-regulation of EIF2-related genes (Fig. 7B, right
panel).4. Discussion
We report here that a unique enteric-colonizing strain, CP2305,
exerted beneficial effects on physical and mental states of pre-
clinical medical students enrolled in a cadaver dissection course.
Similar to medical students in other countries, the students in
the present study were expected to begin the cadaver dissection
course under emotional stress. Unexpectedly, they reported only
mild anxiety, as assessed by the questionnaires. Thus, our students
may be able to rapidly cope with the stressful situation. However,
compared with placebo administration, CP2305 administration
resulted in a small but significant reduction of both STAI-state
and HADS-anxiety scores. Because the course is mentaly demand-
ing, our students progressively complained of abdominal pain and
sleep disturbance, particularly in the placebo group. Notably,
CP2305 administration significantly improved sleep quality. Sleep
quality is an outcome that comprehensively reflects both physical
and psychological conditions (Mollayeva et al., 2016). The benefi-
cial effect of CP2305 on sleep quality is indicative of the potential
benefits of this strain for health promotion.
The beneficial effects of CP2305 ingestion were confirmed not
only subjectively by self-reported questionnaires but also objec-
tively by the assessment of salivary cortisol release andgene expres-
sion profiling in peripheral blood leukocytes. Measurements of
salivary stressmarkers reflect stress responses via both theHPA axis
and the autonomic nerve system. Salivary cortisol, which is a well-
known stress marker, is secreted via the activation of the HPA axis
in response to psychological stress (Kirschbaum & Hellhammer,
1994). CgA and a-amylase are released in response to activation of
Fig. 7. Changes in gene expression profiles of peripheral blood leukocytes. Changes in gene expression in peripheral blood leukocytes were measured using a microarray
before and after the 4-week administration of placebo or CP2305. The cadaver dissection course significantly changed the expression levels of 829 and 1083 genes in the
placebo and CP2305 groups, respectively. (A) IPA analysis listed the top 5 canonical pathways related to the 829 and 1083 affected genes. Dotted lines show the level of
significance (p = 0.05 by Fisher’s exact test). (B) IPA listed ‘‘protein synthesis network” as the top network related to the 829 affected genes in the placebo group (left panel).
Changes in these network-related genes in the CP2305 group are shown in the right panel. Up-regulated and down-regulated genes are shown in red and green, respectively.
(For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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reduction of salivary cortisol concentrations by the administration
of CP2305 suggests that CP2305 suppressed the activation of the
HPA axis. CP2305 ingestion also tended to suppress CgA and a-
amylase levels and may affect autonomic nerve activity.
We employed transcriptome analysis of peripheral blood leuko-
cytes to assess gene expression signatures associated with the ben-
eficial effects of CP2305. Placebo-treated students showed a
prominently reduced expression of EIF2-related genes, and this
reduction was prevented by CP2305 administration. The observed
modification of the EIF2-signal pathway by CP2305 administration
is informative. In response to diverse stress stimuli, eukaryotic
cells activate a common adaptive pathway, termed the integrated
stress response, to restore cellular homeostasis. The core event in
this pathway is the phosphorylation of eIF2a, which leads to a
decrease in global protein synthesis and the induction of selected
genes that together promote cellular recovery (Pakos-Zebrucka
et al., 2016). Recently, we showed that patients with IBS preferen-
tially down-regulated a group of genes related to the EIF2 signal
and that daily intake of CP2305 was able to recover the expression
of these genes, improving IBS severity and health-related worry
(Nobutani et al., 2017). Given that IBS symptoms are also closely
associated with psychosocial stress, the results of this previous
study and the present study suggest that CP2305 may exert
stress-relieving effects at least partially by maintaining EIF2
signal-related gene expression.In the faecal microbiota, cadaver dissection significantly
increased populations of Enterobacteriaceae and Veillonella in the
placebo group, whereas CP2305 ingestion completely prevented
the increases in these well-known inflammatory microbes (Lupp
et al., 2007; Said et al., 2014). It has been suggested that exagger-
ated psychological stress induces inflammatory responses in the
host, which in turn disrupt the intestinal microbiota and promote
the overgrowth of Enterobacteriaceae and Veillonella. Thus, it is
possible that the daily intake of CP2305may correct the psycholog-
ical stress-related imbalance in faecal microbiota.
Elucidating the mechanism for the stress-relieving action of
CP2305 is an important next step. Lactobacillus gasseri strains,
including CP2305, can colonize the human digestive tract
(Fujiwara, Seto, Kimura, & Hashiba, 2001; Sawada et al., 2016).
CP2305 efficiently regulates intestinal functions, even when this
strain is administered as sterilized, washed bacterial cells
(Sugawara et al., 2016). Moreover, elevated parasympathetic nerve
activity has been observed after the continuous ingestion of steril-
ized CP2305 cells (Sugawara et al., 2016). These unique abilities of
CP2305 imply that one or more bacterial cell components may pro-
voke gut signalling by directly interacting with the intestinal
mucosal epithelium or with other cells. These interactions may
effectively regulate higher-order functions of the digestive tract
and induce various biological responses. As a result, CP2305 may
efficiently stimulate the brain-gut axis and influence the stress
response. The improvements in physical and mental states in our
D. Sawada et al. / Journal of Functional Foods 31 (2017) 188–197 197students in the cadaver dissection course suggest that this strain
may sufficiently induce gut signals to produce effects that reach
the central nervous system via the gut-brain axis. Further studies
to test our hypothesis are currently underway.
In conclusion, CP2305 was demonstrated to exert beneficial
effects on medical students under stressful conditions. Our results
suggest that L. gasseri CP2305 has potential benefits for health pro-
motion for mentally and physically distressed subjects.
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